News

AstraZeneca is already in the respiratory syncytial virus market with two products, including the drug Beyfortus, approved earlier this year.An M&A deal will give AstraZeneca an RSV vaccine ...
The monoclonal antibody from Sanofi and AstraZeneca, called Beyfortus, is the first of its kind likely to be widely available to everyone up to 24 months of age beyond a small population of ...
French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus ...
Sanofi, in collaboration with its partner AstraZeneca plc AZN, has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023. Immunizations ...
Beyfortus-maker AstraZeneca enters RSV vaccine race with $800M Icosavax acquisition. By James Waldron Dec 12, 2023 5:19am. AstraZeneca Icosavax respiratory syncytial virus ...
The Beyfortus vaccine alliance between AstraZeneca and Sanofi dates to 2017, when the antibody was still in mid-stage clinical testing. Sanofi paid its new partner €120 million up front; another ...
The approval to AstraZeneca – which is involved in producing the drug – comes about two months after the FDA green-lit the first RSV vaccine for people 60 years and older.
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
Beyfortus (nirsevimab) is a single dose long-acting antibody, developed and commercialised in partnership by AstraZeneca and Sanofi using AstraZeneca’s YTE technology. It is designed to protect ...
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer.
The CDC has announced limited availability of Sanofi immunization Beyfortus for RSV prevention in infants. Here's what parents should know to keep babies safe.